American Society of Hematology

Figure 4.

211At-CD38 therapy in a disseminated MOLP-8Luc model. Mice bearing disseminated MOLP-8Luc xenografts were treated on day 0 with 211At-CD38 or 211At-Ab− at 12, 20, or 28 µCi; n = 10 mice per group. Disease progression was monitored via weekly BLI and thrice weekly observations of mouse weight, condition, and mobility. Mice were euthanized when they experienced hind-limb paralysis or met IACUC weight loss or condition requirements. (A) BLI of untreated control and 12-µCi treatment groups at 7 days posttherapy. (B) BLI of all groups at 21 days posttherapy. Red coffins indicate deceased mice. BLI scale identical to panel A.

²¹¹At-CD38 therapy in a disseminated MOLP-8^Lucmodel. Mice bearing disseminated MOLP-8^Luc xenografts were treated on day 0 with ²¹¹At-CD38 or ²¹¹At-Ab⁻ at 12, 20, or 28 µCi; n = 10 mice per group. Disease progression was monitored via weekly BLI and thrice weekly observations of mouse weight, condition, and mobility. Mice were euthanized when they experienced hind-limb paralysis or met IACUC weight loss or condition requirements. (A) BLI of untreated control and 12-µCi treatment groups at 7 days posttherapy. (B) BLI of all groups at 21 days posttherapy. Red coffins indicate deceased mice. BLI scale identical to panel A.

This Feature Is Available To Subscribers Only